


## PHARMACEUTICAL 2022



## Aeglea BioTherapeutics Inc. Rank 241 of 466





## PHARMACEUTICAL 2022



## Aeglea BioTherapeutics Inc. Rank 241 of 466

The relative strengths and weaknesses of Aeglea BioTherapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aeglea BioTherapeutics Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 24% points. The greatest weakness of Aeglea BioTherapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is 116%, being 38% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	98,891
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	20,144
Liabilities, Non-Current	4,624
Other Assets	6,486
Other Compr. Net Income	-31
Other Expenses	141
Other Liabilities	1,217
Other Net Income	-11
Other Revenues	18,739
Property and Equipment	4,549
Research and Development	57,069
Selling, General and Administrative Expense	27,319

Output Variable	Value in 1000 USD
Assets	109,926
Liabilities	25,985
Expenses	84,529
Revenues	18,739
Stockholders Equity	83,941
Net Income	-65,801
Comprehensive Net Income	-65,816
Economic Capital Ratio	116%

